All Clinical Trials

A listing of 23145 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Trials

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Genetic Analysis of Immune Disorders

NCT00001467

Recruiting

The purposes of this study are to 1) identify the genes responsible for certain immune disorders, 2) learn about the medical problems they cause, and 3) learn how to predict who is likely to develop these disorders and what the risk is of passing them on to children. The immune system is the body s defense system. Some immune deficiencies impair a person s ability to fight infections; others render a person susceptible to allergies, or to autoimmune diseases such as lupus or arthritis, in which the immune cells (white blood cells) attack and destroy the body s own tissues. Patients with immune disorders known or suspected to have a genetic basis and their family members may enroll in this study. Eligibility will be determined by a review of the patient s medical records and family medical history. Participants will provide a small blood sample for genetic (DNA) and white blood cell analysis. Gene samples (but not white blood cells) may also be obtained by mouth brushing or skin biopsy. For the mouth brushing, a small brush is rubbed against the inside of the cheeks for 1 minute to wipe off some cells. For the skin biopsy, a small circle of skin (about 1/8 inch) is removed under local anesthetic. Pregnant women may be asked to provide a fetal sample (amniotic fluid cells or chorionic villus sample). All samples will be used for immune or genetic studies of the family s immune disorder. If test results show a specific genetic variation responsible for the family s immune disorder, a report will be sent to the patient s doctor or genetic counselor, who will discuss the implications for the family. NIH researchers and genetic counselors will also be available to explain results and answer questions. Information will not be available in the case of disorders that cannot yet be linked to a specific genetic abnormality. Information from this study will increase knowledge about the immune system and what causes immune deficiencies. Participants may also learn the underlying cause of an immune disorder that affects them or someone in their family information may be useful in guiding treatment and in making decisions regarding family planning.... Read Less

Gender:

ALL

Ages:

Between 1 day and 101 years

Trial Updated:

06/27/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: DOK 8, STAT1, GATA2, Immunodeficiency, STAT3

Learn More ›

Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer

NCT00033137

Recruiting

This study will investigate the genetic cause of Birt Hogg-Dube (BHD) syndrome and the relationship of this disorder to kidney cancer. BHD is a rare inherited condition characterized by papules, or bumps benign tumors involving hair follicles on the head and neck. People with BHD are at increased risk of developing kidney cancer. Scientists have identified the chromosome (strand of genetic material in the cell nucleus) that contains the BHD gene and the region of the gene on the chromosome. This study will try to learn more about: * The characteristics and type of kidney tumors associated with BHD * The risk of kidney cancer in people with BHD * Whether more than one gene causes BHD * The genetic mutations (changes) responsible for BHD Patients with known or suspected Birt Hogg-Dube syndrome, and their family members, may be eligible for this study. Candidates will be screened with a family history and review of medical records, including pathology reports for tumors, and films of computed tomography (CT) and magnetic resonance imaging (MRI) scans. Participants may undergo various tests and procedures, including the following: * Physical examination * Review of personal and family history with a cancer doctor, cancer nurses, kidney surgeon, and genetic counselor * Chest and other x-rays * Ultrasound (imaging study using sound waves) * MRI (imaging study using radiowaves and a magnetic field) * CT scans of the chest and abdomen (imaging studies using radiation) * Blood tests for blood chemistries and genetic testing * Skin evaluation, including a skin biopsy (surgical removal of a small skin tissue sample for microscopic evaluation) * Cheek swab or mouthwash to collect cells for genetic analysis * Lung function studies * Medical photography of skin lesions These tests will be done on an outpatient basis in either one day or over 3 to 4 days. When the studies are complete, participants will receive counseling about the findings and recommendations. Patients with kidney lesions may be asked to return periodically, such as every 3 to 36 months, based on their individual condition, to document the rate of progression of the lesions. Read Less

Gender:

ALL

Ages:

2 years and above

Trial Updated:

06/27/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Kidney Neoplasms, Kidney Cancer, Pneumothorax, FLCN Protein, Human

Learn More ›

Diagnosis and Treatment of Leishmania Infections

NCT00344188

Recruiting

This study will examine the natural history of Leishmanial infections and their treatments. It will provide an opportunity for NIAID staff to learn more about leishmaniasis and perhaps to improve diagnostic tests for these infections. Patients between 2 and 80 years of age with known or suspected leishmaniasis are eligible for this study. Participants will have routine blood tests and a biopsy to confirm leishmanial infection. The biopsy procedure will be determined by the type of infection local cutaneous leishmaniasis (LCL), mucocutaneous leishmaniasis (MCL) or visceral leishmaniasis (VL). CL will be confirmed with a punch biopsy, in which a cookie-cutter type razor is used to remove a small circular piece of skin tissue. MCL will be confirmed using a thin flexible tube inserted into the nose. This tube is used to examine the nose and upper airway and to remove a tissue sample, if an affected area is seen. VL will be confirmed with either a bone marrow or liver biopsy or a splenic aspirate. For these procedures, a small tissue sample is withdrawn through a needle placed in the hipbone, liver or spleen, respectively. Some patients may also have a skin test for leishmaniasis similar to tuberculin skin testing. Treatment and length of hospital stay are determined by the type of infection. CL may be treated with Pentostam, amphotericin, amphotericin B, itraconazole or ketoconazole; ML with amphotericin B, or encapsulated amphotericin; and VL with Pentostam or encapsulated amphotericin. Pentostam is infused daily for 18 to 28 doses, most as an outpatient. Blood is drawn 3 times a week for safety tests and an electrocardiogram is done 2 to 3 times a week to monitor heart rhythm. Amphotericin B is infused every day or every other day for about 30 doses, all on an inpatient basis. Patients undergo hydration (infusion of a large amount of fluid) just before and immediately after each infusion to protect the kidneys. Blood is drawn every other day and urine samples are collected occasionally for routine urinalysis. Encapsulated amphotericin is infused every other day, on an outpatient basis. Blood is generally drawn every other day to every 2 days and urinalyses are done periodically. Itraconazole and ketoconazole are taken orally for at least 1 to 3 months, with blood drawn every 2 to 3 weeks. Patients may be asked to have photographs taken before, during and after treatment to document progress. They may also be asked to provide extra blood samples for research purposes, either through a vein in the arm or through apheresis, a method for collecting large numbers of cells. For apheresis, whole blood is collected through a needle in an arm vein and circulated through a machine that separates it into its components. The desired cells are then removed, and the rest of the blood is returned to the body, either through the same needle used to draw the blood or through a second needle in the other arm. Patients with cutaneous leishmaniasis will have a follow-up clinic visit 2 weeks to 3 months after treatment is completed. If there are no complications, their participation will end at that time. Patients with mucocutaneous leishmaniasis and visceral leishmaniasis will be followed every 3 to 6 months indefinitely for routine evaluations and re-treatment if the infection recurs. ... Read Less

Gender:

ALL

Ages:

Between 3 years and 100 years

Trial Updated:

06/27/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Leishmaniasis, Skin Diseases, Parasitic, Euglenozoa Infections, Parasitic Diseases

Learn More ›

Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency

NCT01176006

Recruiting

Background: -DOCK8 deficiency is a genetic disorder that affects the immune system and can lead to severe recurrent infections and possible death from infections or certain types of cancers, including blood cancers. A stem cell transplant is a life-saving treatment for this condition. In this study we are evaluating the efficacy and safety of transplant from different donor sources for DOCK8 deficiency. The donors that we are using are matched siblings, matched unrelated donors, and half-matched donors, so called haploidentical related donors, such as mothers or fathers or half-matched siblings. Objectives: -To determine whether transplant of bone marrow cells from different types of donors corrects DOCK8 deficiency. Eligibility: * Donors: Healthy individuals between 2 and 60 years of age who are matched with a recipient. * Recipient: Individuals between 4 and 35 years of age who have confirmed DOCK8 deficiency, have suffered at least one life-threatening infections, or have had certain viral related cancers of cancer and have a stem cell donor. Design: * All participants will be screened with bloodwork, a physical examination and medical history. * DONORS: --Donors who have donate bone marrow cells or blood stem cells will have a sample of blood/bone marrow stored to be compared with the recipients sample after transplant. * RECIPIENTS: * Recipients receiving 10/10 matched related or unrelated donors will receive 4 days of chemotherapy with busulfan and fludarabine to suppress their immune system and prepare them for the transplant. Donors receiving 9/10 matched related or unrelated donors as well as haploidentical related donors will receive 5 days chemotherapy with cyclophosphamide, fludarabine, and busulfan. They will also receive one dose of radiation to suppress their immune system and prepare them for the transplant. * After the initial chemotherapy and radiation (if indicated), recipients will receive the donated stem cells as a single infusion. * After the stem cell transplant, recipients will receive two days of a chemotherapy called cyclophosphamide on day's + 3 and + 4 followed by two drugs tacrolimus and mycophenolate to prevent graft versus host disease where the donor cells attack the patient's body. All patients will remain in the hospital for at least approximately 1 month, and will be followed with regular visits for up to 3 years with periodic visits thereafter to evaluate the success of the transplant and any side effects. Read Less

Gender:

ALL

Ages:

Between 4 years and 120 years

Trial Updated:

06/27/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: DOCK8 Deficiency

Learn More ›

Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes

NCT02107976

Recruiting

Diabetes type two is a debilitating disease that leads to chronic morbidity such as accelerated microvascular disease. Accelerated microvascular disease may produce blindness, end stage renal disease, myocardial infarction, stroke, and limb ischemia. Strategies to prevent or delay microvascular disease have the potential to improve the lives of millions and prevent catastrophic illness. The major focus of prevention of microvascular disease in diabetes has been on the endothelium and its role in protection of blood vessels. An unexpected means to prevent microvascular disease in diabetes may be coupled to the function of vitamin C in red blood cells (RBCs) of diabetic subjects. Based on new and emerging data, vitamin C concentrations in RBCs may be inversely related to glucose concentrations found in diabetes. Based on animal data, we hypothesize that RBCs with low vitamin C levels may have decreased deformability, leading to slower flow in capillaries and microvascular hypoxia, the hallmark of diabetic microangiopathy. Low vitamin C concentrations in RBCs of diabetic subjects may be able to be increased, by using vitamin C supplements. Findings in animals may not accurately reflect effects in humans because of species differences in mechanisms of vitamin C entry into RBCs. Therefore, clinical research is essential to characterize vitamin C physiology in RBCs of diabetic subjects. In this protocol we will investigate physiology of vitamin C in RBCs of diabetic subjects as a function of glycemia, without vitamin C supplementation (stage 1) and with vitamin C supplementation (stage 2). We will screen type II diabetic subjects on insulin and/or oral hypoglycemic medication(s) and select those with hemoglobin A1C concentrations of less than or equal to 12%. Selected subjects may be hospitalized twice, each time for approximately one week. The primary objective of the first hospitalization (stage 1) will be to evaluate the effect of hyperglycemia on vitamin C RBC physiology regardless of baseline vitamin C concentrations (without any vitamin C supplementation). The second hospitalization (stage 2) investigates the effect (if any) of vitamin C supplementation to changes in RBC physiology during euglycemic and hyperglycemic states. As inpatients, subjects will have two venous sampling periods each of approximately 24 hours. On admission, subjects may be fitted with continuous glucose monitors (CGMs), oral hypoglycemic agents will be discontinued, and basal-bolus insulin regimen initiated. Insulin doses will be clinically determined and titrated to achieve euglycemia (fasting and pre-meal glucoses \<140mg/dl) prior to the first sampling period (euglycemic sampling). The first sampling period will be performed under conditions of euglycemic control for 24 hours. The second sampling period will be performed under controlled hyperglycemia induced by withholding basal and bolus insulin and providing a high carbohydrate load diet (70-75% carbohydrate). Correction-scale insulin will be provided for glucoses \>350-400mg/dl. Hyperglycemia will not exceed 9 hours, and will be reversed by reinstituting insulin. During the two sampling periods, samples will be withdrawn via venous catheter for RBC deformability, vitamin C concentrations and other related research studies. Following completion of stage 1, subjects considered for participation in stage 2 will be provided a prescription for vitamin C 500mg twice daily. Given that vitamin C and vitamin E are related antioxidants, and that both vitamins appear to be associated with RBC rigidity, diabetic subjects may also be given a prescription for 400 international units (IU) of vitamin E (RRR alpha tocopherol) daily. Subjects will continue vitamin C and E supplementation for a minimum of 8 weeks depending on RBC vitamin C concentrations. To evaluate any effect of vitamin E supplementation, plasma and RBC vitamin E levels may be measured concurrently with vitamin C levels during various phases of stages 1 and 2. All subjects will be seen as outpatients at biweekly or monthly intervals with regular measurement of plasma and RBC vitamin C concentrations. Target RBC vitamin C concentration \>30uM is required prior to stage 2 inpatient sampling studies. Vitamins C and E supplementation will be discontinued upon inpatient admission for stage 2. Risk of both vitamin supplements are minimal as both supplementation doses are safe. Outcomes are to measure RBC rigidity and vitamin concentrations before and after supplementation. After a minimum of 8 weeks (depending on RBC vitamin C levels), subjects will be hospitalized again, and sampling repeated as described. In this manner, each subject serves as his/her own control, and deformability of red blood cells can be determined in relation to glycemia and to vitamin C concentrations in RBCs and plasma. Read Less

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

06/27/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Diabetes Type 2

Learn More ›

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

NCT02682667

Recruiting

Background: Cancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S. Researchers want to study samples from people with cancer or a pre-malignant condition. They hope to develop more effective treatments. Objective: To better understand the biology of malignancies and why certain cancers respond differently to treatment. Eligibility: Adults at least 18 years old with cancer or a pre-cancerous condition. De... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

06/27/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin, Leukemia-Lymphoma, Adult T-Cell, Hodgkin Disease, Non-Small Cell Lung Cancer

Learn More ›

Biospecimen Procurement for Head and Neck Disorders

NCT03429036

Recruiting

Background: Researchers want to learn more about head and neck disorders. Understanding these disorders could help them find better treatments. To do this, they are collecting tissue samples for research. Objective: To create a repository of tissue samples and data to better study conditions of the head and neck. Eligibility: People who had or will have tissue samples taken because of a head or neck disorder. They must be ages 3 and older and not pregnant to join Part 2. Design: Participa... Read More

Gender:

ALL

Ages:

Between 3 years and 120 years

Trial Updated:

06/27/2025

Locations: MedStar Georgetown University Hospital, Washington, District of Columbia +8 locations

Conditions: Hearing Disorder, Oral Mucosal Disease, Pharyngeal Neoplasm, Head and Neck Neoplasms, Laryngeal Disease

Learn More ›

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

NCT04589845

Recruiting

TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors... Read More

Gender:

ALL

Ages:

All

Trial Updated:

06/27/2025

Locations: Southern Cancer Center, Daphne, Alabama +162 locations

Southern Cancer Center, Daphne, Alabama

Western Regional Medical Center at Cancer Treatment Centers of America, Goodyear, Arizona

City of Hope National Medical Center, Duarte, California

Kaiser Permanente Los Angeles, Los Angeles, California

USC Norris Cancer Center, Los Angeles, California

Hoag Memorial Hospital, Newport Beach, California

UC Davis Comprehensive Cancer Center, Sacramento, California

University of California at San Francisco, San Francisco, California

Sarcoma Oncology Center, Santa Monica, California

Children's Hospital Colorado, Aurora, Colorado

Christiana Care Health Srvcs, Newark, Delaware

University of Florida, Gainesville, Florida

Miami Cancer Institute of Baptist Health, Inc., Miami, Florida

Ocala Oncology Center, Ocala, Florida

University Cancer & Blood Center, LLC, Athens, Georgia

St. Alphonsus, Boise, Idaho

Midwestern Regional Med Center, Zion, Illinois

Horizon Oncology Research, Inc., Lafayette, Indiana

New England Cancer Specialists, Scarborough, Maine

Maryland Hematology & Oncology. P.A., Silver Spring, Maryland

St. Joseph Mercy Hospital, Ann Arbor, Michigan

Henry Ford Health System, Detroit, Michigan

University of Minnesota, Minneapolis, Minnesota

Metro-Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota

Washington University, Saint Louis, Missouri

Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana, Billings, Montana

Nebraska Methodist Hospital, Omaha, Nebraska

Comprehensive Cancer Centers of Nevada - Eastern Avenue, Las Vegas, Nevada

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

University of New Mexico, Albuquerque, New Mexico

Montefiore Einstein Center for Cancer Care, Bronx, New York

Eastchester Center for Cancer Care, Bronx, New York

National Translational Research Group, New York, New York

Icahn School of Medicine at Mount Sinai, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

New York Cancer and Blood Specialists - Setauket Medical Oncology, Port Jefferson Station, New York

Barrett Cancer Center, Cincinnati, Ohio

Oncology Hematology Care Inc, Cincinnati, Ohio

Providence Portland Medical Center, Portland, Oregon

Consultants in Medical Oncology and Hematology, Broomall, Pennsylvania

Alliance Cancer Specialists, Horsham, Pennsylvania

Virginia Cancer Specialists - Leesburg, Leesburg, Pennsylvania

Cancer Treatment Centers of America, Philadelphia, Pennsylvania

The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

PRISMA Health - Greenville, Greenville, South Carolina

The West Clinic, Germantown, Tennessee

St. Jude Children'S Research Hospital, Memphis, Tennessee

Texas Oncology - Central South, Austin, Texas

Mary Crowley Medical Research Center, Dallas, Texas

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas

Cook Childrens Medical Center, Fort Worth, Texas

The University of Texas MD Anderson Cancer Center, Houston, Texas

Texas Oncology- Northeast Texas, Tyler, Texas

Northwest Medical Specialties, PLLC, Tacoma, Washington

Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin

Kinghorn Cancer Centre, Darlinghurst, New South Wales

Sydney Children's Hospital, Randwick, New South Wales

Royal Darwin Hospital, Tiwi, Northern Territory

Princess Alexandra Hospital, Woolloongabba, Queensland

Peter MacCallum Cancer Centre, Melbourne, Victoria

Royal Children's Hospital, Parkville, Victoria

Cliniques Universitaires St-Luc, Bruxelles, Not set

GHdC Site Les Viviers, Charleroi, Not set

UZ Antwerpen, Edegem, Not set

UZ Gent, Gent, Not set

UZ Leuven Gasthuisberg, Leuven, Not set

Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul

Hospital Sírio-Libanês, Sao Paulo, São Paulo

Hospital A. C. Camargo, Sao Paulo, São Paulo

Clínica Onco Star - Rede D'Or, Sao Paulo, São Paulo

BC Cancer ? Vancouver, Vancouver, British Columbia

London Health Sciences Centre · Victoria Hospital, London, Ontario

The Ottawa Hospital - General Campus, Ottawa, Ontario

The Hospital for Sick Children, Toronto, Ontario

Princess Margaret Cancer Center, Toronto, Ontario

McGill University Health Center, Montreal, Quebec

Beijing Cancer Hospital, Beijing, Not set

Beijing Children's Hospital, Capital Medical University, Beijing, Not set

The First Hospital of Jilin University, Changchun City, Not set

Jilin Cancer Hospital, Changchun, Not set

West China Hospital - Sichuan University, Chengdu City, Not set

Shanghai East Hospital, Shanghai City, Not set

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Not set

Zhongshan Hospital Fudan Unvierstiy, Shanghai, Not set

Tianjin Cancer Hospital, Tianjin, Not set

First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, Not set

Aarhus Universitetshospital, Aarhus N, Not set

Rigshospitalet, København Ø, Not set

Institut Bergonie, Bordeaux, Not set

Centre Oscar Lambret, Lille, Not set

Centre Leon Berard, Lyon, Not set

Hopital de la Timone, Marseille, Not set

Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, Not set

Institut de Cancerologie Gustave-Roussy (IGR), Villejuif, Not set

Uniklinik Essen, Essen, Not set

Georg-August-Uniklinik, Göttingen, Not set

Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II, Hamburg, Not set

Medizinische Hochschule Zentrum Innere Medizin Abt.Gastroenterologie, Endokrinologie und Hepatologie, Hannover, Not set

SLK-Kliniken Heilbronn GmbH;Klinik für Innere Medizin III, Heilbronn, Not set

Praxis für Hämatologie, Onkologie und Palliativmedizin, Mönchengladbach, Not set

Klinikum der Universität München, Campus Großhadern, München, Not set

Universtitätsklinikum Ulm, Ulm, Not set

Uniklinikum, Comprehensive Cancer Center Mainfranken, Würzburg, Not set

Hong Kong Children's Hospital, Hong Kong, Not set

Prince of Wales Hospital, Shatin, Not set

Rambam Health Care Campus, Haifa, Not set

Hadassah University Hospital - Ein Kerem, Jerusalem, Not set

Rabin MC, Petach Tikva, Not set

Sheba Medical Center, Ramat Gan, Not set

Sourasky / Ichilov Hospital, Tel Aviv, Not set

Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Campania

Ospedale Pediatrico Bambino Gesù - IRCCS, Roma, Lazio

Policlinico Universitario Agostino Gemelli IRCCS, Roma, Lazio

Asst Degli Spedali Civili Di Brescia, Brescia, Lombardia

Irccs Istituto Nazionale Dei Tumori (Int), Milano, Lombardia

Istituto Nazionale Tumori di Milano, Milano, Lombardia

Dipartimento di Scienze Pediatriche Adolescenza, Torino, Piemonte

Azienda Ospedaliera Meyer, Firenze, Toscana

Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica, Siena, Toscana

National Cancer Center Hospital East, Chiba, Not set

Kindai University Hospital, Osaka, Not set

National Cancer Center Hospital, Tokyo, Not set

Seoul National University Bundang Hospital, Gyeonggi-do, Not set

Seoul National University Hospital- Adult Site, Seoul, Not set

Seoul National University Hospital- Pediatric Site, Seoul, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center- Adult Site, Seoul, Not set

Samsung Medical Center- Pediatric Site, Seoul, Not set

Auckland City Hospital, Cancer and Blood Research, Auckland, Not set

Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gda?sk, Not set

Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad, Warszawa, Not set

IPO do Porto, Porto, Not set

PanOncology Trials, San Juan, Not set

National University Hospital, Singapore, Not set

National Cancer Centre, Singapore, Not set

Medical Oncology Centre of Rosebank, Johannesburg, Not set

Hospital Sant Joan De Deu, Esplugues De Llobregas, Barcelona

Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Not set

Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Not set

Hospital Infantil Universitario Nino Jesus, Madrid, Not set

Clinica Universidad de Navarra Madrid, Madrid, Not set

START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

START Madrid. Centro Integral Oncologico Clara Campal, Madrid, Not set

Hospital Universitario la Fe, Valencia, Not set

Universitätsspital Basel (USB), Basel, Not set

Ospedale Regionale di Bellinzona Medizin Onkologie, Bellinzona, Not set

Inselspital, Klinik und Poliklinik für Medizinische Onkologie, Bern, Not set

Unversitätsspital Zürich, Zürich, Not set

Taichung Veterans General Hospital, Taichung, Not set

National Cheng Kung University Hospital, Tainan, Not set

Taipei Veterans General Hospital, Taipei City, Not set

Chang Gung Memorial Hospital-Linkou, Taoyuan County, Not set

National Taiwan University Hospital, Zhongzheng Dist., Not set

Beatson West of Scotland Cancer Centre, Glasgow, Not set

University College London Hospital, London, Not set

Guys and St Thomas NHS Foundation Trust, Guys Hospital, London, Not set

Royal Manchester Children?s Hospital, Manchester, Not set

The Christie NHS Foundation Trust, Manchester, Not set

Conditions: Solid Tumors

Learn More ›

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

NCT05422612

Recruiting

This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Participants are randomized among the multiple cohorts in the study and the resulting randomization enables sharing/pooling of control participants, where all interventions may be compared to a common control (placebo). This master protocol describes the default procedures and analyses for all cohorts;... Read More

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

06/27/2025

Locations: Phoenix VA Healthcare System, Phoenix, Arizona +7 locations

Conditions: Post Traumatic Stress Disorder

Learn More ›

ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System

NCT05686317

Recruiting

This is a prospective, multi-center, randomized, sham-controlled, double-blinded (participant and outcomes assessor) clinical trial.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/27/2025

Locations: University of California Irvine, Irvine, California +31 locations

University of California Irvine, Irvine, California

University of California San Diego, La Jolla, California

Scripps Health, La Jolla, California

University of Southern California, Los Angeles, California

University of California San Francisco, San Francisco, California

Medical Center of the Rockies, Loveland, Colorado

Ascension Illinois Heart and Vascular Medical Group, Elk Grove, Illinois

Northwestern University, Evanston, Illinois

Kansas University Medical Center, Kansas City, Kansas

Abbott Northwestern Hospital, Minneapolis, Minnesota

Mayo Clinic, Rochester, Minnesota

Montefiore Medical Center, Bronx, New York

University of Buffalo, Buffalo, New York

St. Francis Hospital & Heart Center, Roslyn, New York

The Christ Hospital, Cincinnati, Ohio

The Ohio State University, Columbus, Ohio

Oklahoma Heart Institute, Tulsa, Oklahoma

Oregon Health and Science University, Oregon City, Oregon

Lankenau Medical Center, Wynnewood, Pennsylvania

Medical University of South Carolina Charleston, Charleston, South Carolina

University of Texas Southwestern Medical Center, Dallas, Texas

HCA Houston Healthcare Medical Center, Houston, Texas

Benaroya Virginia Mason, Seattle, Washington

The Ottawa Hospital, Ottawa, Not set

St. Michael's Hospital, Toronto, Not set

Herz- und Diabeteszentrum NRW - Bad Oeynhausen, Bad Oeynhausen, Not set

Herzzentrum Universitätsklinikum Köln, Cologne, Not set

Herzzentrum Dresden GmbH Universitätsklinik für Innere Medizin und Kardiologie, Dresden, Not set

Universitätsklinikum Heidelberg Medizinische Klinik, Heidelberg, Not set

Johannes Gutenberg Universitaet Mainz, Mainz, Not set

Universitätsspital Basel, Basel, Not set

Inselspital Bern, Bern, Not set

Conditions: Heart Failure

Learn More ›

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

NCT06104618

Recruiting

This phase II trial tests how well enfortumab vedotin works for treating patients with squamous cell carcinoma of the penis that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of tumor cells. Enfortumab attaches to a protein called nectin-4 on tumor cells in a targeted way and de... Read More

Gender:

MALE

Ages:

18 years and above

Trial Updated:

06/27/2025

Locations: Mayo Clinic Hospital in Arizona, Phoenix, Arizona +2 locations

Conditions: Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Unresectable Penile Squamous Cell Carcinoma

Learn More ›

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801

Recruiting

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week... Read More

Gender:

ALL

Ages:

Between 16 years and 80 years

Trial Updated:

06/27/2025

Locations: Digestive Health Specialists ( Site 5064), Dothan, Alabama +392 locations

Digestive Health Specialists ( Site 5064), Dothan, Alabama

GI Alliance - Sun City ( Site 5118), Sun City, Arizona

University of Arizona Clinical and Translational Sciences Research Center ( Site 5111), Tucson, Arizona

Clinnova Research ( Site 5110), Anaheim, California

Om Research LLC ( Site 5045), Camarillo, California

Southern California Research Center ( Site 5044), Coronado, California

Om Research LLC ( Site 5038), Lancaster, California

Amicis Research Center - Valencia ( Site 5055), Valencia, California

University of Colorado Anschutz Medical Campus-Division of Gastroenterology and Hepatology ( Site 5026), Aurora, Colorado

Peak Gastroenterology Associates ( Site 5023), Colorado Springs, Colorado

Medical Research Center of Connecticut ( Site 5005), Hamden, Connecticut

Emerson Clinical Research Institute ( Site 5051), Washington, District of Columbia

Gastroenterology Consultants of Clearwater ( Site 5052), Clearwater, Florida

Nature Coast Clinical Research - Inverness ( Site 5042), Inverness, Florida

Atlantic Medical Research ( Site 5073), Margate, Florida

Endoscopic Research Inc ( Site 5061), Orlando, Florida

Orlando Health-Digestive Health Institute ( Site 5010), Orlando, Florida

USF Health Carol and Frank Morsani Center for Advanced Healthcare ( Site 5039), Tampa, Florida

Atlanta Center for Gastroenterology ( Site 5035), Decatur, Georgia

Gastroenterology Associates of Central Georgia ( Site 5048), Macon, Georgia

Eagle Clinical Research ( Site 5089), Chicago, Illinois

University of Chicago Medical Center ( Site 5066), Chicago, Illinois

Endeavor Health ( Site 5018), Evanston, Illinois

GI ALLIANCE - GURNEE ( Site 5003), Gurnee, Illinois

Indiana University Health University Hospital ( Site 5022), Indianapolis, Indiana

Iowa Digestive Disease Center ( Site 5007), Clive, Iowa

Cotton O'Neil Digestive Health Center ( Site 5033), Topeka, Kansas

Massachusetts General Hospital-Crohn's and Colitis Center ( Site 5037), Boston, Massachusetts

University of Michigan ( Site 5060), Ann Arbor, Michigan

Clinical Research Institute of Michigan, LLC ( Site 5002), Clinton Township, Michigan

BVL Research - Kansas ( Site 5099), Liberty, Missouri

Washington University School of Medicine ( Site 5058), Saint Louis, Missouri

HMHN Justice Marie Garibaldi Medical Plaza ( Site 5072), Hackensack, New Jersey

Northwell Health Division of Gastroenterology at Great Neck ( Site 5017), Great Neck, New York

Circuit Clinical /Crystal Run Healthcare LLP ( Site 5050), Middletown, New York

NYU Langone Health - Inflammatory Bowel Disease Center (IBD) ( Site 5078), New York, New York

Weill Cornell Medical College, New-York Presbyterian Hospital ( Site 5079), New York, New York

New York Gastroenterology Associates ( Site 5013), New York, New York

University of North Carolina Medical Center ( Site 5034), Chapel Hill, North Carolina

Atrium Health Gastroenterology MMP ( Site 5105), Charlotte, North Carolina

Javara - Tryon Medical Partners ( Site 5046), Charlotte, North Carolina

Great Lakes Gastroenterology Research, LLC ( Site 5016), Mentor, Ohio

Digestive Disease Specialists Inc. ( Site 5117), Oklahoma City, Oklahoma

Frontier Clinical Research, LLC ( Site 5098), Uniontown, Pennsylvania

University Gastroenterology - Providence - West River Street ( Site 5057), Providence, Rhode Island

Vanderbilt Inflammatory Bowel Disease Clinic ( Site 5049), Nashville, Tennessee

Quality Medical Research ( Site 5114), Nashville, Tennessee

Baylor University Medical Center ( Site 5031), Dallas, Texas

GI Alliance - Dallas - Gaston Avenue ( Site 5054), Dallas, Texas

Baylor College of Medicine Medical Center ( Site 5020), Houston, Texas

GI Alliance - Lubbock ( Site 5012), Lubbock, Texas

Caprock Gastro Research ( Site 5077), Lubbock, Texas

GI Alliance: Mansfield ( Site 5015), Mansfield, Texas

Southern Star Research Institute ( Site 5000), San Antonio, Texas

GI Alliance - Southlake ( Site 5109), Southlake, Texas

Tyler Research Institute ( Site 5001), Tyler, Texas

Richmond VA Medical Center ( Site 5021), Richmond, Virginia

Washington Gastroenterology - Bellevue ( Site 5040), Bellevue, Washington

Swedish Medical Center ( Site 5112), Seattle, Washington

Washington Gastroenterology - Tacoma ( Site 5004), Tacoma, Washington

Concord Repatriation General Hospital-Gastroenterology and Liver Services ( Site 3202), Concord, New South Wales

Royal Brisbane and Women's Hospital ( Site 3200), Brisbane, Queensland

Royal Adelaide Hosp - GI Clinical Trials ( Site 3203), Adelaide, South Australia

Monash Health-Gastroenterology ( Site 3206), Clayton, Victoria

The Alfred Hospital-Gastroenterology ( Site 3201), Melbourne, Victoria

Medizinische Universitaet Innsbruck-Innere Medizin 1 ( Site 0200), Innsbruck, Tirol

Medizinische Universität Wien-Klinik für Innere Medizin III - Abteilung für Gastroenterologie und H ( Site 0202), Vienna, Wien

Uniklinikum Salzburg-Innere Medizin I ( Site 0201), Salzburg, Not set

UZ Gent ( Site 0300), Gent, Oost-Vlaanderen

UZ Leuven-Gastroenterology - Inflammatory Bowel Disease ( Site 0301), Leuven, Vlaams-Brabant

AZ Delta vzw-Gastroenterology ( Site 0304), Roeselare, West-Vlaanderen

Heritage Medical Research Clinic ( Site 0004), Calgary, Alberta

SIX08 Gastroenterology ( Site 0015), Lethbridge, Alberta

Fraser Clinical Trials Inc ( Site 0001), New Westminster, British Columbia

G.I.R.I. GI Research Institute Foundation ( Site 0018), Vancouver, British Columbia

Barrie GI Associates ( Site 0016), Barrie, Ontario

University Hospital - London Health Sciences Centre ( Site 0002), London, Ontario

Victoria Hospital & Children's Hospital - London Health Sciences Centre ( Site 0007), London, Ontario

West GTA Research Inc. ( Site 0020), Mississauga, Ontario

ABP Research Services Corp. ( Site 0019), Oakville, Ontario

Toronto Immune & Digestive Health Institute ( Site 0005), Toronto, Ontario

Toronto Digestive Disease Associates ( Site 0006), Vaughan, Ontario

Centre de recherche du CISSS de Chaudière-Appalaches - Hôpital Hôtel Dieu de Levis ( Site 0011), Levis, Quebec

Montreal General Hospital ( Site 0003), Montreal, Quebec

Diex Recherche Quebec ( Site 0008), Quebec, Not set

Hospital hernan henriquez aravena de temuco ( Site 2607), Temuco, Araucania

Hospital Clínico Regional Dr. Guillermo Grant Benavente ( Site 2604), Concepción, Biobio

FALP-UIDO ( Site 2600), Santiago, Region M. De Santiago

Clínica Alemana de Santiago-Unidad de Investigaciones ( Site 2602), Santiago, Region M. De Santiago

Espacio Eme ( Site 2608), Santiago, Region M. De Santiago

CECIM ( Site 2603), Santiago, Region M. De Santiago

Centro de Investigaciones Clinicas Vina del Mar ( Site 2606), Vina del Mar, Valparaiso

Anhui Provincial Hospital ( Site 3922), Hefei, Anhui

Peking University Third Hospital ( Site 3910), Beijing, Beijing

Chongqing General Hospital ( Site 3940), Chongqing, Chongqing

The First Affiliated Hospital Of Fujian Medical University ( Site 3916), Fuzhou, Fujian

The First Affiliated hospital of Xiamen University ( Site 3924), XiaMen, Fujian

Zhongshan Hospital Affiliated to Xiamen University ( Site 3923), Xiamen, Fujian

Dongguan People's Hospital ( Site 3933), Dongguan, Guangdong

The First Affiliated Hospital, Sun Yat-sen University ( Site 3901), Guangzhou, Guangdong

The Sixth Affiliated Hospital of Sun Yat-sen University ( Site 3907), Guangzhou, Guangdong

Huizhou Municipal Central Hospital ( Site 3915), Huizhou, Guangdong

The University of Hong Kong-Shenzhen Hospital ( Site 3930), Shenzhen, Guangdong

Shenzhen Hospital of Southern Medical University ( Site 3932), Shenzhen, Guangdong

The Second Afilliated Hospital of Hebei Medical University ( Site 3913), Shijiazhuang, Hebei

The Second Affiliated Hospital of Zhengzhou University ( Site 3909), Zhengzhou, Henan

Taihe Hospital ( Site 3944), Shiyan, Hubei

Renmin Hospital of Wuhan University ( Site 3921), Wuhan, Hubei

The Second Xiangya Hospital of Central South University-gastroenterology department ( Site 3905), Changsha, Hunan

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 3937), Nanjing, Jiangsu

Zhongda Hospital Southeast University-Gastroenterology ( Site 3911), Nanjing, Jiangsu

Wuxi People's Hospital ( Site 3925), Wuxi, Jiangsu

Affiliated Hospital of Jiangsu University ( Site 3919), Zhenjiang, Jiangsu

Changzhou No.2 People's Hospital ( Site 3904), Zhenjiang, Jiangsu

Tangdu Hospital of Fourth Military Medical University of Chinese People's Liberation Army ( Site 3918), Xian, Shaanxi

Ruijin Hospital Shanghai Jiaotong University School of Medicine ( Site 3931), Shanghai, Shanghai

Huashan Hospital of Fudan University ( Site 3946), Shanghai, Shanghai

Shanghai East Hospital ( Site 3914), Shanghai, Shanghai

West China Hospital, Sichuan University ( Site 3929), Cheng Du, Sichuan

Suining Central Hospital ( Site 3927), SuiNing, Sichuan

First Affiliated Hospital of Kunming Medical University ( Site 3928), Kunming, Yunnan

Sir Run Run Shaw Hospital of Zhejiang University School of Medicine-GI Medicine ( Site 3902), Hangzhou, Zhejiang

Taizhou Hospital of Zhejiang Province ( Site 3936), Taizhou, Zhejiang

Clinica Medellin S.A ( Site 2705), Medellín, Antioquia

IMAT S.A.S ( Site 2700), Monteria, Cordoba

Oncologos del Occidente ( Site 2702), Pereira., Risaralda

Fundación Valle del Lili ( Site 2704), Cali., Valle Del Cauca

Poliklinika Bates ( Site 0504), Zagreb, Grad Zagreb

Poliklinika Solmed ( Site 0502), Zagreb, Grad Zagreb

Poliklinika Borzan ( Site 0500), Osijek, Osjecko-baranjska Zupanija

Institut Klinicke a Experimentalni Mediciny-Klinika hepatogastroentrologie ( Site 0654), Praha, Praha 4

Hepato-Gastroenterologie HK ( Site 0652), Hradec Kralove, Not set

Herlev and Gentofte Hospital ( Site 5300), Copenhagen, Hovedstaden

Odense Universitetshospital ( Site 5301), Odense C, Syddanmark

Tampereen yliopistollinen sairaala ( Site 5401), Tampere, Pirkanmaa

Pohjois-Karjalan Keskussairaala ( Site 5403), Joensuu, Pohjois-Karjala

Turku University Hospital ( Site 5402), Turku, Varsinais-Suomi

Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 0711), Nice, Alpes-Maritimes

CHU Bordeaux Haut-Leveque ( Site 0713), Pessac, Aquitaine

Assistance Publique Hôpitaux de Marseille - Hôpital Nord ( Site 0722), Marseille, Bouches-du-Rhone

Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand ( Site 0708), Dijon, Bourgogne

Centre Hospitalier Universitaire de Reims - Hôpital Robert Debré ( Site 0707), Reims cedex, Champagne-Ardenne

CHU Besançon ( Site 0724), Besançon, Doubs

Centre Hospitalier de Valence ( Site 0725), Valence, Drome

C.H.U. de Nimes. Hopital Caremeau ( Site 0731), Nimes, Gard

CHU Rangueil ( Site 0710), Toulouse, Haute-Garonne

Hopital Beaujon ( Site 0729), Clichy, Hauts-de-Seine

CMC Ambroise Paré Hartmann - Institut des MICI ( Site 0723), Neuilly-sur-Seine, Hauts-de-Seine

Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre ( Site 0702), Kremlin Bicetre, Ile-de-France

CHU SAINT ELOI ( Site 0701), Montpellier, Languedoc-Roussillon

Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu ( Site 0705), Nantes, Loire-Atlantique

Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois ( Site 0717), Vandoeuvre-les-Nancy, Meurthe-et-Moselle

Hopital Claude Huriez - CHU de Lille ( Site 0715), Lille, Nord

centre hospitalier lyon sud ( Site 0716), Pierre-Bénite, Rhone

CHU d'Amiens-Picardie - Hôpital Sud ( Site 0709), Amiens, Somme

Hopital Henri Mondor ( Site 0730), Creteil, Val-de-Marne

Hôpital Saint Antoine ( Site 0721), Paris, Not set

LTD High Technology Hospital Medcenter ( Site 0802), Batumi, Ajaria

Caucasus Medical Centre ( Site 0801), Tbilisi, Ajaria

New Hospitals ( Site 0800), Tbilisi, Not set

Caraps Medline ( Site 0803), Tbilisi, Not set

Siloah St. Trudpert Klinikum-Zentrum für Innere Medizin ( Site 0992), Pforzheim, Baden-Wurttemberg

Klinikum der Universität München Großhadern ( Site 0990), München, Bayern

klinikum rechts der isar der technischen universität münchen ( Site 0989), München, Bayern

Universitaetsklinikum Ulm. ( Site 0994), Ulm, Bayern

Universitätsmedizin Rostock ( Site 0993), Rostock, Mecklenburg-Vorpommern

Medizinische Hochschule Hannover ( Site 0999), Hannover, Niedersachsen

Klinikum Lüneburg ( Site 0991), Lüneburg, Niedersachsen

Stadtische Kliniken Duisburg, Abtlg. Innere Medizin ( Site 0985), Duisburg, Nordrhein-Westfalen

Evangelisches Krankenhaus Kalk gGmbH ( Site 0986), Koln, Nordrhein-Westfalen

Gastroenterologische Gemeinschaftspraxis Minden ( Site 0998), Minden, Nordrhein-Westfalen

Medizinisches Versorgungszentrum Portal 10 ( Site 0988), Münster, Nordrhein-Westfalen

Magen Darm Zentrum Remscheid ( Site 0984), Remscheid, Nordrhein-Westfalen

St. Marien und St. Annastift Krankenhaus ( Site 0987), Ludwighafen Am Rhein, Rheinland-Pfalz

Universitätsklinikum Leipzig ( Site 0997), Leipzig, Sachsen

Universitaetsklinikum Schleswig-Holstein Campus Kiel ( Site 0995), Kiel, Schleswig-Holstein

Charité Campus Virchow-Klinikum ( Site 0996), Berlin, Not set

Städtisches Klinikum Brandenburg ( Site 0903), Brandenburg, Not set

Evangelismos General Hospital of Athens ( Site 1002), Athens, Attiki

THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 1004), Athens, Attiki

General Hospital of Nikaia-Piraeus "Agios Panteleimon" ( Site 1003), Nikaia Piraeus, Attiki

Ippokrateio General Hospital of Thessaloniki ( Site 1001), Thessaloniki, Kentriki Makedonia

University General Hospital of Heraklion-GASTROENTEROLOGY & HEPATOLOGY ( Site 1000), Heraklion, Kriti

Queen Mary Hospital ( Site 3300), Hksar, Not set

Békés Megyei Központi Kórház Dr. Réthy Pál Tagkórház-4. Belgyogyaszat Gasztroenterologia ( Site 1105), Békéscsaba, Bekescsaba

Heves Vármegyei Markhot Ferenc Oktatókórház és Rendelőintézet ( Site 1117), Eger, Heves

Gyöngyösi Bugát Pál Kórház ( Site 1111), Gyongyos, Heves

Komarom-Esztergom Varmegyei Szent Borbala Korhaz ( Site 1115), Tatabánya, Komarom-Esztergom

VeszLife Magánklinika ( Site 1102), Veszprém, Veszprem

Clinexpert Kft.-Clinexpert Budapest ( Site 1108), Budapest, Not set

Synexus Magyarorszag Kft. (Budapest DRS) ( Site 1107), Budapest, Not set

Pannónia Magánorvosi Centrum ( Site 1103), Budapest, Not set

Emek Medical Center ( Site 1206), Afula, Not set

Barzilai Medical Center ( Site 1209), Ashkelon, Not set

Rambam Health Care Campus ( Site 1201), Haifa, Not set

Bnai Zion Medical Center ( Site 1203), Haifa, Not set

Edith Wolfson Medical Center ( Site 1204), Holon, Not set

Shaare Zedek Medical Center ( Site 1208), Jerusalem, Not set

Meir Medical Center. ( Site 1202), Kfar Saba, Not set

Rabin Medical Center ( Site 1207), Petah Tikva, Not set

Sheba Medical Center ( Site 1200), Ramat Gan, Not set

Policlinico Universitario Monserrato-SC Gastroenterologia ( Site 1313), Monserrato, Cagliari

Fondazione Policlinico Tor Vergata ( Site 1307), Rome, Lazio

Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico-Gastroenterology and Endoscopy Unit ( Site 1304), Milano, Lombardia

Istituto Clinico Humanitas-IBD center ( Site 1309), Rozzano, Lombardia

A.O.R.N. Ospedale dei Colli - Monaldi V. ( Site 1310), Napoles, Napoli

Ospedale "Felice Lotti" Di Pontedera ( Site 1311), Pontedera, Pisa

A.O.U.C. Policlinico di Bari ( Site 1306), Bari, Puglia

Az. Osp. Ospedali Riuniti VILLA SOFIA-CERVELLO-U.O.S.D. Malattie Infiammatorie Croniche Intestinali ( Site 1302), Palermo, Sicilia

Ospedale Sacro Cuore Don G. Calabria-IBD Unit ( Site 1303), Negrar Di Valpolicella, Verona

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1308), Bologna, Not set

Azienda Ospedaliera Universitaria Di Messina G. Martino ( Site 1314), Messina, Not set

Ospedale San Raffaele-Gastroenterology and Gastrointestinal Endoscopy ( Site 1300), Milano, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Dipartimento di Medicina Interna e Gas ( Site 1312), Roma, Not set

Aichi Medical University Hospital ( Site 3429), Nagakute, Aichi

Nagoya University Hospital ( Site 3445), Nagoya,, Aichi

Nagoya City University Hospital ( Site 3446), Nagoya, Aichi

Tokatsu Tsujinaka Hospital ( Site 3403), Abiko, Chiba

Tsujinaka Hospital - Kashiwanoha ( Site 3402), Kashiwa, Chiba

Toho University Sakura Medical Center ( Site 3413), Sakura, Chiba

Kurume University Hospital ( Site 3419), Kurume, Fukuoka

Gunma University Hospital ( Site 3432), Maebashi, Gunma

National Hospital Organization Fukuyama Medical Center ( Site 3442), Fukuyama, Hiroshima

Sapporo Tokushukai Hospital ( Site 3427), Sapporo, Hokkaido

Sapporo Medical University Hospital ( Site 3460), Sapporo, Hokkaido

Medical Corporation Sapporo IBD Clinic ( Site 3420), Sapporo, Hokkaido

Sapporohigashi Tokushukai Hospital ( Site 3441), Sapporo, Hokkaido

Hyogo Medical University Hospital ( Site 3430), Nishinomiya, Hyogo

Hitachi General Hospital ( Site 3438), Hitachi, Ibaraki

Kanazawa University Hospital ( Site 3436), Kanazawa, Ishikawa

Iwate Medical University Uchimaru Medical Center ( Site 3457), Morioka, Iwate

Gokeikai Ofuna Chuo Hospital ( Site 3412), Kamakura, Kanagawa

St. Marianna University Hospital ( Site 3440), Kawasaki, Kanagawa

Matsushima Hospital ( Site 3450), Yokohama, Kanagawa

Yokohama City University Medical Center ( Site 3439), Yokohama, Kanagawa

Mie University Hospital ( Site 3405), Tsu, Mie

Tohoku University Hospital ( Site 3447), Sendai, Miyagi

University of the Ryukyus Hospital ( Site 3459), Ginowan, Okinawa

Kansai Medical University Hospital ( Site 3409), Hirakata, Osaka

Saitama Medical Center ( Site 3452), Kawagoe, Saitama

Hamamatsu University Hospital ( Site 3449), Hamamatsu, Shizuoka

Matsuda Hospital ( Site 3404), Hamamatsu, Shizuoka

National Hospital Organization Shizuoka Medical Center ( Site 3401), Shimizu, Shizuoka

Institute of Science Tokyo Hospital ( Site 3437), Bunkyō, Tokyo

Ginza Central Clinic ( Site 3407), Chuo, Tokyo

Kitasato University Kitasato Institute Hospital ( Site 3458), Minato, Tokyo

Kyorin University Hospital ( Site 3443), Mitaka, Tokyo

The Jikei University Hospital ( Site 3414), Mitato, Tokyo

Tokyo Medical University Hospital ( Site 3456), Shinjuku, Tokyo

National Center for Global Health and Medicine ( Site 3423), Shinjuku, Tokyo

Yamanashi Prefectural Central Hospital ( Site 3435), Kofu, Yamanashi

Fukuoka University Hospital ( Site 3417), Fukuoka, Not set

Hiroshima University Hospital ( Site 3418), Hiroshima, Not set

Kagoshima University Hospital ( Site 3425), Kagoshima, Not set

Kagoshima IBD Gastroenterology Clinic ( Site 3428), Kagoshima, Not set

University Hospital,Kyoto Prefectural University of Medicine ( Site 3406), Kyoto, Not set

National Hospital Organization Kyoto Medical Center ( Site 3411), Kyoto, Not set

Okayama University Hospital ( Site 3454), Okayama, Not set

Infusion Clinic ( Site 3408), Osaka, Not set

National Hospital Organization Osaka National Hospital ( Site 3453), Osaka, Not set

Saga University Hospital ( Site 3424), Saga, Not set

Tokyo Yamate Medical Center ( Site 3415), Tokyo, Not set

Toyama Prefectural Central Hospital ( Site 3410), Toyama, Not set

Yamagata University Hospital ( Site 3426), Yamagata, Not set

Wonju Severance Christian Hospital-Internal Medicine ( Site 3600), Wonju, Kang-won-do

The Catholic University Of Korea St. Vincent's Hospital-Gastroenterology ( Site 3608), Suwon-si, Kyonggi-do

Dong-A University Hospital ( Site 3601), Busan, Pusan-Kwangyokshi

Inje University Haeundae Paik Hospital ( Site 3605), Haeundae-gu, Pusan-Kwangyokshi

Chung-Ang University Hospital ( Site 3606), Dongjak-gu, Seoul

Yeungnam Univeristy Medical Center ( Site 3610), Daegu, Taegu-Kwangyokshi

The Catholic University of Korea, Daejeon St. Mary's Hospital ( Site 3604), Daejeon, Taejon-Kwangyokshi

Kyung Hee University Hospital ( Site 3611), Seoul, Not set

Seoul National University Hospital ( Site 3607), Seoul, Not set

Kangbuk Samsung Hospital-Internal Medicine ( Site 3612), Seoul, Not set

The Catholic University of Korea, Eunpyeong St. Mary's Hospital ( Site 3602), Seoul, Not set

Severance Hospital, Yonsei University Health System-Department of Internal Medicine ( Site 3603), Seoul, Not set

Asan Medical Center ( Site 3609), Seoul, Not set

Samsung Medical Center ( Site 3613), Seoul, Not set

Hospital of Lithuanian University of Health Sciences Kauno klinikos-Gastroenterology ( Site 6000), Kaunas, Kauno Apskritis

VILNIUS UNIVERSITY HOSPITAL SANTAROS KLINIKOS-Department of Clinical Trials and Pharmacology ( Site 6001), Vilnius, Not set

Hospital Sultanah Aminah ( Site 6104), Johor Bahru, Johor

Hospital Universiti Sains Malaysia ( Site 6103), Kubang Kerian, Kelantan

University Malaya Medical Centre ( Site 6101), Lembah Pantai, Kuala Lumpur

Sarawak General Hospital ( Site 6102), Kuching, Sarawak

Hospital Ampang ( Site 6106), Ampang, Selangor

Centro de Investigación y Gastroenterología - S.C. ( Site 3102), Ciudad de Mexico, Distrito Federal

Morales Vargas Centro de Investigacion ( Site 3101), Leon, Guanajuato

Centro Medico Clinico Quirurgico Especializado en Investigación ( Site 3106), Tlajomulco de Zúñiga, Jalisco

Servicios de Oncología Médica Integral, S.A de C.V. ( Site 3108), San Pedro Garza Garcia, Nuevo Leon

Centro de Investigacion Clinica de Oaxaca ( Site 3105), Oaxaca de Juarez, Oaxaca

Medical Care and Research SA de CV-GASTROENTEROLOGY ( Site 3110), Merida, Yucatan

Radboudumc ( Site 1505), Nijmegen, Gelderland

ETZ Elisabeth ( Site 1501), Tilburg, Noord-Brabant

Ziekenhuis Bernhoven ( Site 1508), Uden, Noord-Brabant

Amsterdam UMC, locatie VUmc-IBD Trial Unit ( Site 1500), Amsterdam, Noord-Holland

Erasmus Medisch Centrum ( Site 1504), Rotterdam, Zuid-Holland

Franciscus Gasthuis & Vlietland, Locatie Gasthuis ( Site 1503), Rotterdam, Zuid-Holland

University Medical Center Groningen ( Site 1506), Groningen, Not set

Universitair Medisch Centrum Utrecht ( Site 1502), Utrecht, Not set

Dunedin Hospital ( Site 3505), Dunedin, Otago

Hutt Valley District Health board HVDHB ( Site 3500), Lower Hutt, Wellington

Aotearoa Clinical Trials ( Site 3501), Auckland, Not set

Investigaciones Clínicas / Instituto de Ginecología y Reproducción ( Site 3002), Lima, Not set

Hospital Cayetano Heredia ( Site 3003), Lima, Not set

Amicare ( Site 1620), Jelenia Gora, Dolnoslaskie

Planetmed ( Site 1600), Wroclaw, Dolnoslaskie

Melita Medical ( Site 1607), Wroclaw, Dolnoslaskie

EMC Instytut Medyczny SA ( Site 1601), Wroclaw, Dolnoslaskie

Gastromed Sp. z o. o. ( Site 1619), Torun, Kujawsko-pomorskie

Centrum Medyczne Med-Gastr Sp. z o.o. ( Site 1616), Lodz, Lodzkie

AmiCare Sp. z o.o. Sp. k. ( Site 1608), Lodz, Lodzkie

Allmedica ( Site 1602), Nowy Targ, Malopolskie

Centrum Zdrowia MDM ( Site 1618), Warszawa, Mazowieckie

WIP Warsaw IBD Point Profesor Kierkuś ( Site 1622), Warszawa, Mazowieckie

H-T Centrum Medyczne Endoterapia ( Site 1610), Tychy, Slaskie

PL Certus ( Site 1605), Poznan, Wielkopolskie

Pratia Poznań ( Site 1603), Poznań, Wielkopolskie

Twoja Przychodnia - Szczecinskie Centrum Medyczne ( Site 1612), Szczecin, Zachodniopomorskie

Sonomed Sp. z o. o. ( Site 1617), Szczecin, Zachodniopomorskie

Unidade Local de Saúde do Alto Ave - Hospital Senhora da Oliveira ( Site 1704), Guimaraes, Braga

Unidade Local de Saude do Algarve - Hospital de Portimão ( Site 1700), Portimão, Faro

Unidade Local de Saude da Região de Leiria - Hospital Santo André ( Site 1706), Leiria, Not set

Hospital da Luz Lisboa ( Site 1707), Lisboa, Not set

Hospital dos Lusíadas Lisboa ( Site 1701), Lisboa, Not set

ULSAM - Hospital de Santa Luzia ( Site 1703), Viana do Castelo, Not set

Unidade Local de Saude Dão-Lafões - Hospital de São Teotónio ( Site 1702), Viseu, Not set

MEMORIAL HEALTHCARE INTERNATIONAL S.R.L ( Site 1806), Bucharest, Bucuresti

Fundeni Clinical Institute-Gastroenterology and Hepatology Center ( Site 1808), București, Bucuresti

GastroMed ( Site 1809), Cluj-Napoca, Cluj

Spitalul Clinic Judetean Mures-Gastroenterology ( Site 1807), Targu Mures, Mures

ASOCIATIA ONCOHELP ( Site 1805), Timisoara, Timis

S.C. Centrul Medical Medicum SRL-Gastroenterology ( Site 1804), Bucuresti, Not set

Clinical Hospital Center Zvezdara-Gastroenterology and hepatology Department ( Site 1903), Belgrade, Beograd

General Hospital "Djordje Joanovic" ( Site 1905), Zrenjanin, Srednjebanatski Okrug

Singapore General Hospital ( Site 6202), Singapore, Central Singapore

Tan Tock Seng Hospital-Gastroenterology and Hepatology ( Site 6201), Singapore, Central Singapore

Changi General Hospital ( Site 6203), Singapore, South East

Fakultna nemocnica s poliklinikou F.D.Roosevelta Banska Bystrica-Gastroenterologicke oddelenie ( Site 2002), Banska Bystrica, Banskobystricky Kraj

Cliniq s.r.o. ( Site 2001), Bratislava, Bratislavsky Kraj

KM Management ( Site 2000), Nitra, Nitriansky Kraj

GASTRO I ( Site 2004), Presov, Presovsky Kraj

Gastro LM ( Site 2005), Presov, Presovsky Kraj

Panorama Medical Centre ( Site 4001), Cape Town, Western Cape

Spoke Research ( Site 4003), Cape Town, Western Cape

Life Kingsbury Hospital ( Site 4000), Cape Town, Western Cape

Private Practice - Dr. M.N. Rajabally ( Site 4007), Plumstead, Western Cape

Hospital Germans Trias i Pujol ( Site 2101), Badalona, Barcelona

HOSPITAL CLÍNIC DE BARCELONA-ICMDM - Clinical Institute of Digestive and Metabolic Diseases ( Site 2112), Barcelona, Cataluna

Hospital Universitario Puerta de Hierro ( Site 2102), Majadahonda, Madrid

Hospital Universitario de Torrejón ( Site 2108), Torrejón de Ardoz, Madrid

Hospital Universitario La Paz ( Site 2100), Madrid, Not set

Hospital Montecelo. Complexo Hospitalario de Pontevedra ( Site 2107), Pontevedra, Not set

Hospital Universitario Nuestra Senora de la Candelaria ( Site 2105), Santa Cruz de Tenerife, Not set

HOSPITAL CLINICO DE VALENCIA-MEDICINA DIGESTIVA ( Site 2103), Valencia, Not set

Hospital Universitari i Politecnic La Fe ( Site 2111), Valencia, Not set

Hospital Universitario Miguel Servet ( Site 2104), Zaragoza, Not set

Universitetssjukhuset i Linköping ( Site 5502), Linköping, Ostergotlands Lan

Danderyds Sjukhus ( Site 5501), Danderyd, Stockholms Lan

Karolinska Universitetssjukhuset Solna ( Site 5500), Stockholm, Stockholms Lan

University Hospital Basel-Gastroenterology and Hepatology ( Site 2204), Basel, Basel-Stadt

INTESTO-Gastroenterologische Praxis / Crohn-Colitis Zentrum Bern ( Site 2202), Bern, Berne

Cantonal Hospital St.Gallen-Klinik für Gastroenterologie / Hepatologie ( Site 2201), St.Gallen, Sankt Gallen

UniversitätsSpital Zürich-Gastroenterologie & Hepatologie ( Site 2200), Zürich, Zurich

National Taiwan University BioMedical Park Hospital ( Site 3702), Zhu Bei City, Hsinchu

National Taiwan University Hospital-Internal Medicine ( Site 3700), Taipei, Not set

Chang Gung Medical Foundation-Linkou Branch ( Site 3701), Taoyuan, Not set

Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 2300), Ankara, Not set

ANKARA UNIVERSITY IBNI SINA HOSPITAL-Gastroenterology ( Site 2303), Ankara, Not set

Ankara Bilkent Şehir Hastanesi-Gastroenterology ( Site 2301), Ankara, Not set

Antalya Egitim ve Arastırma Hastanesi ( Site 2304), Antalya, Not set

Istanbul Universitesi Cerrahpasa Tip Fakultesi Hastanesi ( Site 2306), Istanbul, Not set

Marmara Univetsitesi Pendik Egitim ve Arastirma Hastanesi ( Site 2305), Istanbul, Not set

Ege Universitesi Hastanesi ( Site 2302), İzmir, Not set

Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Site 5815), Ivano-Frankivsk, Ivano-Frankivska Oblast

Medical Center of Limited ( Site 5806), Kyiv, Kyivska Oblast

Center of Family Medicine Plus ( Site 5803), Kyiv, Kyivska Oblast

Communal Non-profit Enterprise of Lviv Regional Council "Lviv Regional Clinical Hospital"-proctology ( Site 5809), Lviv, Lvivska Oblast

Limited liability company "Medical center Health Clinic" ( Site 5807), Vinnytsia, Vinnytska Oblast

Clinic of Scientific and Research Institute of Invalid Rehabilitation of VNMU n.a. M.I.Pyrohov ( Site 5812), Vinnytsia, Vinnytska Oblast

Communal Non-Commercial Enterprise "Vinnytsia City Clinical -Clinical Therapeutic Department #1 ( Site 5811), Vinnytsia, Vinnytska Oblast

Municipal Nonprofit Enterprise "Vinnytsia Regional Clinical Hospital n.a. M. I. Pyrohov of Vinnytsia ( Site 5814), Vinnytsya, Vinnytska Oblast

Municipal Enterprise "Volyn Regional Clinical Hospital" of Volyn Regional Council ( Site 5813), Lutsk, Volynska Oblast

Medical Center "Universal Clinic "Oberig" of Limited Liability Company "Kapytal" ( Site 5800), Kyiv, Not set

Dobrobut Medical Center ( Site 5801), Kyiv, Not set

Medical Center of Private Enterprise "Sygma" ( Site 5808), Kyiv, Not set

Royal Devon & Exeter Hospital ... ( Site 2407), Exeter, Devon

Doncaster Royal Infirmary ( Site 2401), Doncaster, England

Huddersfield Royal Infirmary ( Site 2409), Huddersfield, England

Whipps Cross University Hospital-Clinical Research Unit ( Site 2404), London, England

University College London Hospital-Clinical Research Facility ( Site 2405), London, London, City Of

The John Radcliffe Hospital ( Site 2406), Oxford, Oxfordshire

Southmead Hospital ( Site 2403), Bristol, South Gloucestershire

Walsall Manor Hospital ( Site 2410), West Midlands, Walsall

Conditions: Crohn's Disease

Learn More ›